FEC filings through Oct 14, 2026 · FEC bulk filing data · committee C00030809 · files monthly
SummaryAt a glance
Why it exists
No statement of purpose found on its site.
Money
$719.4K raised, $744.6K spent, $247.4K cash on hand (through Oct 14, 2026). Where it comes from
Who funds it
84% from donors giving over $200 · 11% from donors giving $200 or less · largest donor Cencora, Inc. PAC, $10K. See who funds it
Where it goes
$703.1K given to candidates and committees, the largest to NRCC ($30K) · 57% of its support to Republicans, 36% to Democrats. See where it goes
Lobbying
National Community Pharmacists Association lobbied on 8 issues. See lobbying
Audits and penalties
1 audit report and 2 administrative fines, published by the FEC
Its wordsWhat does this committee say it is for?
No published list of positions
This committee’s site publishes no list of positions we could read, and we found no statement of why it exists. We do not write one for it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$387K to 109 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $387,000
Republican 57%
Democratic 36%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Republican
58
$219,000
$0
$219,000
57%
Democratic
38
$138,000
$0
$138,000
36%
Other or unresolved
13
$30,000
$0
$30,000
7.8%
Shown support
109
$387,000
$0
$387,000
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$703,100 in 277 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
38
$138K · 20%
Republican candidates
58
$219K · 31%
Other or unresolved candidates
13
$30K · 4.3%
Other party committees
4
$120K · 17%
Other PACs and committees
34
$196.1K · 28%
All recipients
147
$703.1K
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
New York
10
$35.5K
Texas
9
$24K
North Carolina
5
$22K
Kentucky
2
$20K
New Jersey
6
$20K
Virginia
5
$20K
Alabama
5
$18K
Georgia
4
$17K
The largest 8 of 43 states.
Recipients 147
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Shelley Moore Capito3 receipts, latest Oct 1, 2026Capito for West Virginia · S4WV00159$10K
Jake Auchincloss4 receipts, latest Jan 21, 2026Jake Auchincloss for Congress · H0MA04192$10K
James Michael Johnson2 receipts, latest Feb 5, 2025Mike Johnson for Louisiana · H6LA04138$10K
James Comer4 receipts, latest Sep 17, 2026Comer for Congress · H6KY01110$10K
Vicente Gonzalez4 receipts, latest May 19, 2026Vicente Gonzalez for Congress · H6TX15162$10K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
Committees funding this one
Name
Amount
Cencora, Inc. PACPAC (qualified) · Connected to CENCORA, INC. · 2 payments
Michael Vinson18 contributions, latest Aug 29, 2026 · OWNER · ADAMS DRUGS · MONTGOMERY, AL$6,624
Charles D. Cottrell15 contributions, latest Jun 2, 2026 · OWNER · MEDICAL CENTER PHARMACY · BREWTON, AL$6,240
Brian Hoey15 contributions, latest Apr 20, 2026 · CEO · NATIONAL COMMUNITY PHARMACISTS ASSOCIA · ALEXANDRIA, VA$6,240
Sherry Middleton14 contributions, latest Feb 21, 2026 · OWNER · FAMILY PHARMACY · LEXINGTON, TN$5,824
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 2,834 itemized contributions were filed this cycle, totaling $550K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$82,19311%
PACs and other committeesPolitical action committees and other candidates' committees.$20,0002.8%
Committees that gave
Cencora, Inc. PAC2 receipts, latest Jan 28, 2026 · Pac (qualified)$10,000
The 3 largest committees by total given are listed. Counted from the givers' own filings, which can run above the total this committee reports.
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$15,5002.2%
Total reported receipts $719,408
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. Open a source marked + to see who gave. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $549,981 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $2.7K
$2.7K+
$10.9K+
$24.5K+
$43.5K+
none
Top states
Top donor states
Name
Amount
New York319 contributions · 12%
$67,948
Alabama223 contributions · 9.4%
$51,571
Texas234 contributions · 6.9%
SpendingWhere does the money go?
How the spending splits $744,624 reported
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$718,60097%
Paid to
NRCC2 payments · latest Jan 21, 2026 · CONTRIBUTION$30,000
NRSC2 payments · latest Jan 21, 2026 · CONTRIBUTION$30,000
DCCC2 payments · latest Jan 21, 2026 · CONTRIBUTION$30,000
DSCC2 payments · latest Jan 21, 2026 · CONTRIBUTION$30,000
Bankcard2 payments · latest Jan 3, 2025 · BANK FEES$70
Other disbursementsEverything the committee reports outside the lines above.$6,7000.9%
Contribution refundsMoney returned to the people and committees that gave it.$58<0.1%
Total reported disbursements $744,624
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $722,366 itemized
Given to othersContributions to other candidates, party committees, and PACs.$703,10097%
Filed as
CONTRIBUTION$703,100
Paid to
NRCC$30,000
NRSC$30,000
DCCC$30,000
DSCC$30,000
Moderate Democrats PAC$10,000
Republican Governance Group/tuesday Group PAC$10,000
Card paymentsPaid to a card processor with no itemisation filed beneath it, so the purchases behind it are not on the record.$19,1962.7%
Filed as
CREDIT CARD PROCESSING FEES$17,420
CREDIT CARD PROCESSING FEE$1,777
Paid to
Stripe$15,064
Paypal$3,835
Snowball$298
Taxes, fees, and bank chargesPayroll and income taxes, filing fees, bank and merchant processing charges.$70<0.1%
Filed as
Spending over time
$749K spent from Jan 2025 to Oct 2026. Most in one report: $161.1K, February 2025.
$749K
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Published by the Commission against this committee’s own FEC ID. An audit is a periodic examination that reports findings; an administrative fine is a penalty for filing a specific report late or not at all. They are separate instruments and are not combined into a score here.
Audit reports
1
Fines assessed
2
Penalties assessed
$1.4K
Audit findings
2000 cycleReport released Jul 23, 2002
No Findings or Issues/Not a CommitteeNo Findings or Issues
Source: the Commission’s audit-case and administrative-fine records, joined on this committee’s FEC ID, imported Oct 26, 2026. Enforcement matters (MURs) are published only against respondent names, with no committee identifier, so they are not shown here rather than being matched by name.
LobbyingWhat does its sponsor lobby on?
What National Community Pharmacists Association lobbies on 2026 reports
Besides giving through its PAC, National Community Pharmacists Association pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$960K
Quarterly reports read
9
Bills it named
48
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Medicare/Medicaidin 6 report entries · 18 bills named
In its own words
S.891, the Bipartisan Health Care Act;
S.882, the Patients Before Middlemen Act;
S.927, the Protecting Pharmacies in Medicaid Act;
H.R.3164/S.2426, the Mainstreet Pharmacy Access Act/the Ensuring Community Access to Pharmacist Services Act;
H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act;
Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA;
P.L. 117-169);
Long-Term Care Pharmacy at Home Services in Medicare;
Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA;
P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program";
Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection;
Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form";
H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
H.R.4317, the PBM Reform Act;
H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act;
Comments to CMS on "RE:Re: Medicare Program;
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]";
Comments to CMS on "Re: Medicare and Medicaid Programs;
Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update;
Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model;
Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates;
DMEPOS Accreditation Requirements;
Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]";
Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]";
CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies;
Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]";
H.R.5256, the 340B ACCESS Act;
S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act;
S.3345, the PBM Price Transparency and Accountability Act;
H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act;
Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care;
CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs;
H.R.7148, the Consolidated Appropriations Act, 2026;
Comments to CMS on Proposed Rule "Re: Medicare Program;
Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program";
Implementation of "reasonable and relevant" contract terms in the Medicare Part D Program;
Patient Protection and Affordable Care Act;
Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges [CMS-0062-P]";
Comments to CMS on "Re: Medicare GLP-1 Bridge Program - Improper Restriction of the $5.00 LTC Dispensing Fee to Nursing Facility and ICF/IID Residents;
Conflict with 42 C.F.R. 423.120, Chapter 5, Section 20.7 of the Medicare Prescription Drug Benefit Manual, and CMSs December 15, 2021 Guidance on LTC Pharmacy Access";
Comments to CMS on "Re: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program [CMS-4215-P]";
CY 2027 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies;
Medicare Shared Savings [CMS-1848-P]";
S. 5496, Health CARE Act of 2026;
S. 5586, Ensuring Accurate Payments to Specialty Pharmacies Act
H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act;
Monitoring legislative and regulatory issues related to pharmacies.
Medicaid prescription drug reimbursement.
Pharmacy Benefit Manager provisions included in Public Law No. 119-75 - H.R. 7148 and H.R. 3164, the Main Street Pharmacy Access Act.
Monitoring legislative and regulatory issues related to pharmacies. Medicaid prescription drug reimbursement. Pharmacy Benefit Manager provisions included in H.R. 1 the One Big Beautiful Bill Act (OBBB) P.L. 119-21.
H.R. 2214, the Delinking Revenue from Unfair Gouging Act;
H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025;
H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
H.R. 1, the One Big Beautiful Bill;
Comments to FDA on "Re: Agency Information Collection Activities;
Proposed Collection;
Comment Request;
Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]";
LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms;
Comments to OMB on "Re: Request for Information: Deregulation";
Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs;
Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients";
Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting";
H.R.5316, the Drug Shortage Compounding and Patient Access Act;
H.R.5256, the 340B ACCESS Act;
Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy";
Alcohol and Drug Abusein 3 report entries
In its own words
Controlled Substances Prescribing & Dispensing;
Comments to DOJ & DEA on "Ensuring Lawful Governance and Implementing the Presidents 'Department of Government Efficiency' Deregulatory Initiative";
Comments to DEA on "Special Registrations for Telemedicine and Limited State Telemedicine Registrations [Docket No. DEA-407]" Comments to DEA on "Update to DEA Registration Process for Pharmacists to Reflect State Law Changes"
Offices it contacted
Drug Enforcement Administration (DEA)
HOUSE OF REPRESENTATIVES
Justice, Dept of (DOJ)
SENATE
Budget/Appropriationsin 3 report entries · 6 bills named
In its own words
H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025;
H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
H.R.1, the One Big Beautiful Bill Act;
H.R.5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026;
H.R.7148, the Consolidated Appropriations Act of 2026;
TRICARE Pharmacy Network Oversight & Changes; H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027; H.R. 6400/S.4106,the RxACCESS Act; Veterans Affairs Health Pharmacy Program;
TRICARE Pharmacy Network Oversight & Changes; H.R.8800/S.4784, the National Defense Authorization Act for Fiscal Year 2027; H.R. 6400/S.4106,the RxACCESS Act;
TRICARE Pharmacy Network Oversight & Changes; National Defense Authorization Act for Fiscal Year 2026; H.R. 6400/S.4106,the RxACCESS Act;
Legislative and regulatory issues related to independent pharmacists. PBM Issues, including H.R./S._Modernizing and Ensuring PBM Accountability Act. H.R./S._Lower Costs, More Transparency Act.
Legislative and regulatory issues related to independent pharmacists. PBM reform, including implementation of Public Law No. 119-75. DoD / TRICARE pharmacy benefit program audit.
Legislative and regulatory issues related to independent pharmacists. PBM reform, including implementation of Public Law No. 119-75
Offices it contacted
Executive Office of the President (EOP)
Federal Trade Commission (FTC)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
Labor Issues/Antitrust/Workplacein 3 report entries · 5 bills named
In its own words
S.526, the Pharmacy Benefit Manager Transparency Act of 2025;
S.527, the Prescription Pricing for the People Act of 2025;
Comments to Department of Labor RE: "Re: Reforming Pharmacy Benefit Manager (PBM) Compensation Practices";
H.R.7895, the PBM Kickback Prohibition Act;
Comments to DOL on "Re: Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure [RIN 1210-AB37]"' Comments to DOJ on "Re: NCPA Comment on Competitor Collaboration Guidance (Docket No. ATR-2026- 0001)"' H.R.8779/S.4509, the Patients Before Monopolies Act;
Comments to the White House on the Corporate Transparency Act implementations (NDAA; P.L.116-283); Comments to Treasury on the Corporate Transparency Act implementations (NDAA; P.L.116-283);
Comments to the White House on the Corporate Transparency Act implementations (NDAA; P.L.116-283);
Offices it contacted
White House Office
Treasury, Dept of
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
National Community Pharmacists AssociationIts own staff · 3 reports$960K
Capitol Counsel LLCLobbying firm · 3 reports$150K
BGR Government AffairsLobbying firm · 3 reports$80K
Contributions on the LD-203 report
Reported twice a year by the lobbying filer. $211.8K is political giving that also appears in FEC filings.
DCCC$15K
DSCC$15K
NRCC$15K
NRSC$15K
ACROSS THE AISLE PAC$5K
AMERICAN REVIVAL PAC$5K
BLUE DOG POLITICAL ACTION COMMITTEE$5K
CHC BOLD PAC$5K
HEARTLAND VALUES PAC$5K
HISPANIC LEADERSHIP TRUST$5K
Matched by name: these reports are filed for “NATIONAL COMMUNITY PHARMACISTS ASSOCIATION”, found by searching “NATIONAL COMMUNITY PHARMACISTS ASSOCIATION -”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 27, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
National Community Pharmacists Association - PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names National Community Pharmacists Association as an affiliate. Official FEC summary: Federal Election Commission committee record.
Pages quoted 0 pages
No pages quoted
Nothing from this committee’s or its sponsor’s site is quoted yet.
Linked public records
No approved organization identity yet
The official FEC committee record remains available under Filings.
$703.1K across 146 recipient committees, or 94% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
$38,050
Tennessee125 contributions · 5.8%
$32,063
Georgia190 contributions · 5.7%
$31,425
Pennsylvania121 contributions · 4.5%
$24,863
Oklahoma149 contributions · 4.2%
$23,300
Washington87 contributions · 4%
$22,136
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
National Community Pharmacists Associa223 contributions · 3.4% of ranked
$16,277
American Home Pharmacy18 contributions · 2.1% of ranked
$10,128
Paas National2 contributions · 2.1% of ranked
$10,000
Tanglewood Pharmacy36 contributions · 2.1% of ranked
$9,920
Compliant Pharmacy Alliance Cooperativ21 contributions · 1.9% of ranked
$8,820
Anderson Drugs And Home Care Center20 contributions · 1.8% of ranked
$8,320
Chancy Drugs20 contributions · 1.8% of ranked
$8,320
Medical Center Pharmacy20 contributions · 1.8% of ranked
$8,320
Ranked from the largest 200 of 201 employer spellings filed; each share is of the money in those. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($82,193) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
Owner/manager1,149 contributions · 43% of ranked
$236,447
Owner699 contributions · 26% of ranked
$144,368
Pharmacist231 contributions · 7.2% of ranked
$39,410
President134 contributions · 6.4% of ranked
$35,414
CEO65 contributions · 2.4% of ranked
$13,042
Chief Executive Officer29 contributions · 2.2% of ranked
$12,064
President And CEO24 contributions · 1.5% of ranked
$8,311
Pharmacist/owner25 contributions · 1% of ranked
$5,250
A further $187 came from donors whose answer names no occupation (N/A, blank), so it is not ranked. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($82,193) are not itemized, so no employer or occupation is filed for them.
BANK FEES
$70
Paid to
Bankcard$70
Total itemized disbursements $722,366
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 1,149 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities;
S.3345, the PBM Price Transparency and Accountability Act;
H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act;
H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act];
H.R. 6703, the Lower Health Care Premiums for All Americans Act;
H.R.5133, the Patient's Right to Know Their Medication Act;
H.R. 4409, the Fair Pharmacies for Federal Employees Act;
S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act;
H.R.7148, the Consolidated Appropriations Act of 2026;
Rural Health Transformation Program;
Creation and Implementation of TrumpRx;
Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs;
Request for Information";
S.3822, Break up Big Medicine Act;
Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism";
Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]";
Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool;
H.R. 7895, the PBM Kickback Prohibition Act;
Comments to FDA on their comment request "Re: Agency Information Collection Activities;
Medication Guides for Prescription Drug Products [FDA-2025-N-6869]";
H.R.6509/S.3794, the SAFE Drug Act;
H.R.5316, the Drug Shortage Compounding Patient Access Act;
H.R.8779/S.4509, the Patients Before Monopolies Act;
S.3788/H.R.8269, the CLEAR LABELS Act;
S.1941, the Cure Hepatitis C Act of 2025;
Comments to Senate Finance "Re: Request for Information: Commonsense Policy Options to Lower Drug Prices for Patients";
H.R. 8630, the PEAT Act;
Comments to HHS, ASPE on "RE: Docket No. HHS-OS-2026-0332 for Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making;
H.R. 10369, Net Effective Cost Transparency and Prescription Drug Affordability Act;
Provide strategic counsel and advocate on issues related to health care legislative and regulatory issues.